Additionally, a recent study showed that a low expression level of ST3GAL5 correlates with increased tumorigenesis and progression of bladder cancer, highlighting its potential as a predictive biomarker as well as a therapeutic target [41]. Here, ST3GAL5 is linked to urinary bladder carcinoma.